High-Sensitivity C-Reactive Protein is a Prognostic Biomarker of Six-Month Disability after Traumatic Brain Injury: Results from the TRACK-TBI Study
| Autor: | Mary J. Vassar, Sonia Jain, David O. Okonkwo, Joseph T. Giacino, Ross C. Puffer, Ava M. Puccio, Pratik Mukherjee, Xiaoying Sun, Ramon Diaz-Arrastia, Amy J. Markowitz, Sabrina R Taylor, Kevin K.W. Wang, Esther L. Yuh, Linda B. Xu, Claudia S. Robertson, Geoffrey T. Manley, Miri Rabinowitz, Sureyya Dikmen, Murray B. Stein, John K. Yue, Michael McCrea, Ethan A. Winkler, Hansen Deng, Nancy R. Temkin, Harvey S. Levin, Frederick K. Korley |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Male Traumatic 030506 rehabilitation Biomedical Research Time Factors Systemic inflammation 0302 clinical medicine Brain Injuries Traumatic Prospective Studies biology traumatic brain injury Injuries and accidents Middle Aged Prognosis C-Reactive Protein head trauma Biomarker (medicine) Female medicine.symptom 0305 other medical science Adult medicine.medical_specialty Physical Injury - Accidents and Adverse Effects Traumatic brain injury TRACK-TBI Investigators Clinical Sciences Traumatic Brain Injury (TBI) 03 medical and health sciences Young Adult Clinical Research Internal medicine medicine Humans Prognostic biomarker Disabled Persons Traumatic Head and Spine Injury Neurology & Neurosurgery business.industry C-reactive protein Neurosciences biomarkers Original Articles medicine.disease nervous system diseases Brain Disorders nervous system Brain Injuries biology.protein Neurology (clinical) business Biomarkers 030217 neurology & neurosurgery |
| Zdroj: | Journal of neurotrauma, vol 38, iss 7 J Neurotrauma |
| Popis: | Systemic inflammation impacts outcome after traumatic brain injury (TBI), but most TBI biomarker studies have focused on brain-specific proteins. C-reactive protein (CRP) is a widely used biomarker of inflammation with potential as a prognostic biomarker after TBI. The Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study prospectively enrolled TBI patients within 24 h of injury, as well as orthopedic injury and uninjured controls; biospecimens were collected at enrollment. A subset of hospitalized participants had blood collected on day 3, day 5, and 2 weeks. High-sensitivity CRP (hsCRP) and glial fibrillary acidic protein (GFAP) were measured. Receiver operating characteristic analysis was used to evaluate the prognostic ability of hsCRP for 6-month outcome, using the Glasgow Outcome Scale-Extended (GOSE). We included 1206 TBI subjects, 122 orthopedic trauma controls (OTCs), and 209 healthy controls (HCs). Longitudinal biomarker sampling was performed in 254 hospitalized TBI subjects and 19 OTCs. hsCRP rose between days 1 and 5 for TBI and OTC subjects, and fell by 2 weeks, but remained elevated compared with HCs (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|